Change search
ReferencesLink to record
Permanent link

Direct link
Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)
Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Tage Hansens Gade 2, DK-8000 Aarhus, Denmark..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Endocrinology and mineral metabolism.
Orleans Hosp, Orleans, France..
Eli Lilly & Co, Windlesham, Surrey, England..
Show others and affiliations
2016 (English)In: Calcified Tissue International, ISSN 0171-967X, E-ISSN 1432-0827, Vol. 99, no 3, 259-271 p.Article in journal (Refereed) Published
Abstract [en]

We describe the pre-planned interim analysis of fracture outcomes, health-related quality of life (HRQoL) and back pain in patients with severe osteoporosis treated with teriparatide for up to 24 months in the Extended Forsteo (Forsteo(A (R)) is a registered trade name of Eli Lilly and Company) Observational Study (ExFOS), a prospective, multinational, observational study. Data on incident clinical fractures, HRQoL (EQ-5D questionnaire) and back pain [100 mm visual analogue scale (VAS)] were collected. The number of patients with fractures was summarised in 6-month intervals and fracture rate over each 6-month period was assessed using logistic regression for repeated measures. Changes from baseline in EQ-5D and back pain VAS were analysed using mixed models for repeated measures. Of 1454 patients in the active treatment cohort, 90.6 % were female and 14.4 % were taking glucocorticoids. During teriparatide treatment (median duration 23.7 months), 103 patients (7.1 %) sustained a total of 122 incident clinical fractures (21 % vertebral, 79 % non-vertebral). A 49 % decrease in the odds of fractures and a 75 % decrease in the odds of clinical vertebral fractures were observed in the > 18- to 24-month period versus the first 6-month period (both p < 0.05). EQ-5D scores and back pain VAS scores were significantly improved from baseline at each post-baseline observation during teriparatide treatment. In conclusion, patients with severe osteoporosis showed a significant reduction in the incident fracture rate during 24 months of teriparatide treatment in routine clinical practice, accompanied by a significant improvement in HRQoL and reduction in back pain. Results should be interpreted in the context of the non-controlled design of this observational study.

Place, publisher, year, edition, pages
2016. Vol. 99, no 3, 259-271 p.
Keyword [en]
Osteoporosis, Observational study, Teriparatide, Fractures, Quality of life, Back pain
National Category
Endocrinology and Diabetes
Identifiers
URN: urn:nbn:se:uu:diva-303024DOI: 10.1007/s00223-016-0143-5ISI: 000380264800006PubMedID: 27137783OAI: oai:DiVA.org:uu-303024DiVA: diva2:970778
Available from: 2016-09-14 Created: 2016-09-14 Last updated: 2016-09-14Bibliographically approved

Open Access in DiVA

fulltext(693 kB)16 downloads
File information
File name FULLTEXT01.pdfFile size 693 kBChecksum SHA-512
9e83ac8155fa224ce4de6cfd48911bb3867bad3a06a995f4a473a3bd3cd8c04e3e43d1ac55368f7321bc57463486149d6d7f886ddf375f52bcf83f23d3bb09a0
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ljunggren, Östen
By organisation
Endocrinology and mineral metabolism
In the same journal
Calcified Tissue International
Endocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar
Total: 16 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 19 hits
ReferencesLink to record
Permanent link

Direct link